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(NOACs), 5.2% on antiplatelets (AP) and 11.0% on VKA+AP combinations. In the 
“convenience” dimension, the overall score (0-100 range) was 82.9 ±17.3. The score 
was higher in the NOAC group (88.1 ± 13.0) compared to the VKA (82.1 ± 17.5), AP (87.0 
± 17.9) or VKA +AP groups (83.2 ± 16.8), respectively. In the “anticoagulant treatment 
satisfaction” dimension of the PACT-Q2, the overall score was 63.4 ±15.9. Again, 
this score was higher in the NOAC group (66.6 ±16.6) compared to the VKA (63.2 
±15.9), AP (63.7 ±16.8), or VKA + AP groups (62.8 ±15.0), respectively. ConClusions: 
Overall, patients on current anticoagulation achieve relatively high values on the 
convenience scale, but moderate values on the satisfaction scale. While differences 
in group size and patient characteristics need to be taken into account, patients 
on NOACs compared to patients on VKAs tend to rate their convenience and treat-
ment satisfaction higher.
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objeCtives: Aim of the study was to investigate whether chronic patients are 
willing to pay an extra amount of money in order to switch to another drug that it 
is either on patent, more effective or simpler in dose. Methods: A cross-sectional 
study was conducted among 1600 chronic patients suffering from diabetes, hyper-
tension, COPD and Alzheimer. Logistic regression analysis was carried out to explore 
the factors that influence patients’ decision on willingness to pay (WTP) for an 
alternative drug with innovative characteristics. Results: Of the 1600 patients 
approached, 1594 responded to the survey (99.6%). A total of 40% stated that they 
would be willing to pay more for a patent drug, 57.5% for a more effective drug and 
37.5% for a simpler in dose drug. The average additional amount per month that 
they would be willing to spend was estimated at 23.6€ for a patent drug, 24.1€ for a 
more effective drug and 21.9€ for a simpler in dose drug. Statistical analysis revealed 
that WTP for a patent drug was statistically significant related with the patient’s 
income (OR,1.24;95%CI, 1.14-1.34) while WTP for a more effective or a simpler in dose 
drug was positively related with the patient’s income (OR,1.25;95%CI, 1,13-1,39 and 
OR, 1,14;95%CI, 1.05-1.24 respectively) and educational level (OR,1.06;95%CI, 1,01-
1.13 and OR, 1.06;95%CI, 1.01-1.13, respectively). ConClusions: Half of chronic 
patients demonstrate absolute willingness to increase spending for an innovative 
drug, which highlights the significance they attribute to pharmaceuticals for the 
management of their condition. The remaining’s 50% reluctance may be attributed 
to the extended trust on their current pharmaceutical treatment and to the efforts 
and money spent in order to control their condition. However, patients with higher 
socioeconomic status are more likely to express WTP which reflects the economic 
burden imposed by chronic conditions, and the role of education in shaping patient 
attitudes.
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objeCtives: Identification of differences in the length of hospital stay for patients 
with atrial fibrillation (AF) with and without oral anticoagulation (OA). Longer 
stays of patients could lead to an economical burden for the hospital because 
of the Diagnosis Related Groups (DRG) system in Germany and the compensa-
tion with case-based lump sum. Methods: We conducted a retrospective study 
using an electronic DRG benchmarking database. This database contains DRG 
data from 208 hospitals in Germany with over 2,800,000 inpatient cases per year. 
In total, 10,912,922 cases from the year 2010 to 2012 were analyzed. 661,845 cases 
fulfilled the inclusion criteria and were analyzed according the statistical analy-
sis plan including matched pair analyses. Results: Cases with AF and surgical 
intervention compared to cases without AF and with surgical intervention have 
a significantly longer pre-operation length of stay (+0.74 days) and a significantly 
longer hospital stay (+1.5 days). Furthermore cases with chronic AF (= AF+OA) 
have a significantly longer total length of stay in the hospital (+0.86 days). For 
the cases with AF and bleeding vs. cases without bleeding, there is no significant 
difference in the total length of stay, but there is a significantly longer stay of 0.82 
days compared to the average length of stay in the DRG-catalogue. ConClusions: 
Patients with AF and with or without OA could be an economic burden for the 
hospital, because the increased length of stay in hospital leads to higher costs 
whereas the existing compensation diagnosis-based lump sum is not affected by 
increased treatment days. The new oral anticoagulants could lead to shorter stays 
of patients with AF by shortening the bridging periods compared to OA like vitamin 
K antagonists. Further studies should be conducted to figure out the causes for 
longer hospital stays of patients with AF.
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patients with diabetes, HRQoL was lower across all health dimensions measured 
by the EQ-5D; except mobility and self-care. Individualised therapeutic manage-
ment programs could be considered in order to improve the HRQoL of CAD patients 
with diabetes.
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objeCtives: Patient Perception of Arrhythmia Questionnaire (PPAQ) is a disease-
specific questionnaire designed to measure symptoms and health-related quality of 
life in patients suffering from a group of arrhythmias collectively called supraven-
tricular tachycardias (SVT). There is no valid translation of PPAQ available in Poland, 
which hinders research in this area with Polish arrhythmia patients. The aim of 
this study was to conduct initial content validity testing through translation and 
cultural adaptation of the English language version of the PPAQ to the Polish lan-
guage. Methods: The whole project was conducted according to ISPOR Principles 
of Good Practice for the Translation and Cultural Adaptation Process for Patient-
Reported Outcomes (PRO) Measures published in 2005. Results: In 2011, the PPAQ 
was translated into Polish and cultural adaptation was performed on 20 patients 
with SVT (12 male, age 54.9±17.4). Issues concerning close meanings of symptom 
names and language-dependant gender-related distinctions were identified. The 
former was solved by cooperation with experts in arrhythmia and latter by incor-
porating patients’ preferences during cognitive debriefing. ConClusions: The 
Polish translation was well accepted by patients during this translation and initial 
content validity testing. Issues arisen during the translation process may recur in 
other translations and be resolved in similar manner.
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objeCtives: Atrial fibrillation (AF) 5-folds stroke risk, which results in death or dis-
ability in 80% of individuals and one-year mortality approaches 50%. The objective of 
the present study was to analyze the health-related quality of live (HRQoL) one year 
post-stroke in patients with or without AF and the burden of caregivers. Methods: 
We performed an observational, multicenter, naturalistic and prospective study that 
included 16 stroke units from different Spanish regions. We used EQ-5D and VAS to 
test patients HRQoL and Zarit Burden Inventory to estimate the caregiver burden. 
We collected information at hospital entry for patients, 3 and 12 months post-
stroke both for patients and carers through direct physician interviews. Results: 
A total of 321 stroke patients were recruited, 160 with and 161 without AF. EQ-5D 
was completed by 274 patients - 127 with AF and 147 without AF -, and VAS by 249 
- 113 with and 136 without AF -. The average utility scores of EQ-5D were 0.57, 0.62, 
and 0.65. We found a statistically significant difference between AF and non-AF 
obtained at hospital entry (p= 0.029) and 12 months post-stroke (p= 0.023). There 
were no differences between hospital visits (p= 0.112). If we took into consideration 
the age of patients, the absence or presence of AF in EQ-5D scores, lost its signifi-
cance (p= 0.099). VAS average scores were 45.81, 44.15 and 45.74. VAS results showed 
non-significant differences neither by AF presence (p= 0.396) nor time (p= 0.613). 
Caregiver burden was higher in AF than non-AF patientes (46.47 vs 40.93 2nd visit 
and 45.29 vs 38.73 3rd visit) and the difference was statistically significant (p= 0.007 
and p= 0.002). ConClusions: Stroke has a deep impact on patients HRQoL with 
no improvement over time. In the same line, caregivers also support an important 
burden related to stroke and specially in AF patients.
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objeCtives: The great majority of patients with atrial fibrillation (AF) require anti-
coagulation in order to prevent strokes or other thromboembolic events. We aimed 
at obtaining detailed and current information on patients’ satisfaction with their 
ongoing anticoagulation treatment. Methods: PREFER in AF (The PREvention oF 
thromboembolic events – European Registry in Atrial Fibrillation) is a current non-
interventional study performed in France, Germany, Austria, Switzerland, Italy, 
Spain and UK. A total of 7243 consecutive patients with ECG-confirmed AF in the 
previous 12 months are followed up prospectively. The ‘Perception of Anticoagulant 
Treatment Questionnaire’ is a valid and reliable instrument that allows the assess-
ment of patients’ expectations (PACT-Q1) and satisfaction regarding anticoagu-
lant treatment, as well as patients’ opinion about treatment convenience of use 
(PACT-Q2). Results: A total of 5049 patients (69.7%) received antithrombotic treat-
ment and were willing to fill out the PACT-Q2 questionnaire at baseline. 77.1% 
of these were on vitamin K antagonists (VKAs), 6.4% on new oral anticoagulants 
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objeCtives: Price erosion is considered the key success criterion of generic 
drug policies. For chronic drug therapy, however, persistence with the original 
drug substance is equally important. Low persistence may result in poor health 
outcomes, lead to increased health care costs. Our objective was to estimate the 
impact of switching drug therapy on health and economic outcomes as a conse-
quence of the Hungarian drug policy in hypertension. Methods: We retrieved 
4-year medical records of hypertensive patients, who had at least 10 prescriptions 
of original losartan or losartan HCT in the 12 months prior to patent expiry. We 
allocated patients to 3 groups based on switching history in the 12 months after 
patent expiry. Group 1 patients were switched to another patented antihyperten-
sive product without risk for generic substitution (n= 953). Group 2 patients were 
switched to generic losartan or losartan HCT, but did not change the generic brand 
in 12 months (n= 630). Group 3 patients were switched at least twice among differ-
ent generic brands in 12 months (n= 1144). We calculated the incidence of major 
cardiovascular events (MACE) and overall health care cost (289.42 HUF/EUR 2012 
average exchange rate) in each group. Results: Total 3-year health care costs were 
€ 9,728, € 6,594, € 8,227, the incidence of MACEs was 13.3%, 9.8%, 12.3% in Group 1, 2 
and 3 respectively. ConClusions: In chronic diseases switching to generic drugs 
reduces health care costs. However, frequent switching among generic brands may 
result in negative health outcomes and increased health care costs. Suboptimal 
implementation of generic drug policies in chronic diseases may compromise 
expected benefits (i.e. same health gain at lower costs). Potential confounding fac-
tors may limit the generalizability of our conclusions.
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objeCtives: There are two important success criteria of generic drug policies in 
chronic diseases after patent expiry: price erosion and persistence. Our objective 
was to assess the implementation of generic drug policies on these criteria between 
2007-2011 in Hungary by comparing the continuation of angiotensin receptor block-
ers after patent expiry of original therapies. Methods: In Hungary the first generic 
losartan was launched in 2007; losartan HCT in 2009; valsartan/valsartan HCT in 
2011. From the National Health Insurance Fund database, we selected prescription 
records of hypertensive patients with at least 10 prescriptions of original losar-
tan (Group 1; n= 2637), losartan HCT (Group 2; n= 7598) and valsartan/valsartan 
HCT (Group 3; n= 38098) in the last 12 months prior to patent expiry. We compared 
antihypertensive therapies in 12 months after the reimbursement of first generic 
drug in each group. Antihypertensives were categorized into preferred (continued 
antihypertensive therapy with same active ingredient generic drugs), and non-pre-
ferred (continuation on original drug therapy; switching to other patented drug(s) 
without risk for generic substitution; switching to generic drugs with other active 
ingredient(s); discontinuation of reimbursed antihypertensive drug therapies) policy 
outcomes. Results: After patent expiry 76.2% and 68.9% of Group 1&2 patients 
continued the original losartan or losartan HCT therapy for 12 months, and only 
3.9% and 8.5% were switched to generic losartan/losartan HCT. In Group 3, 33.6% 
of patients were switched to generic valsartan/valsartan HCT, 42.8% received other 
generic drugs or drug combinations, whilst 14.5% were switched to other patented 
products. ConClusions: Despite significant changes in the generic drug policies 
in Hungary in 2007, 2009 and 2011 not more than one-third of hypertensive patients 
changed to generic drugs during 12 months after first generic entry. These findings 
indicate suboptimal generic drug policy in a chronic disease with significant public 
health implications.
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objeCtives: To review the consumption pattern of ambulatory high expenditure 
therapeutic groups in Portugal following prescribing guidelines set forth by the 
Memorandum of Understanding; to perform a cross-country comparison of utili-
zation patterns focusing on quality prescribing indicators identified by the EURO-
MED-STAT and/or major international prescribing guidelines; and to perform a 
cost-saving scenario analysis if more rational European prescribing patterns were 
undertaken in Portugal. Methods: Cross-national drug utilization study with 
data from seven European countries: Portugal, Denmark, England, Finland, The 
Netherlands, Norway and Sweden. Data from Portugal retrieved from hmR Pharmacy 
Sales Information System, a nationwide database with representative pharmacy 
dispensing data. Data from other countries was selected from published literature 
and/or public databases. Cost-saving analysis with assumptions: average annual 
cost per defined daily dose (DDD) from Portugal and simulations to measure the 
impact on total expenditure of international utilization patterns (DDD proportion) 
versus Portuguese pattern. Results: Portugal has the highest consumption of 
oral antidiabetic combinations (19.3% in 2010), of Antagonists Reception Blockers 
(ARBs) (31% in 2009), and of rosuvastatin (22.2% in 2011). A total of 236 Million euro 
annual cost-savings was estimated in scenarios of more rational prescribing: 100 
Million euro (58% decrease in costs of antidiabetic agents in 2010) when simulating 
the Dutch oral antidiabetic prescribing pattern; 106 Million euro when simulating 
the Danish antihypertensive prescribing pattern (20% decrease in antihypertensive 
costs in 2009); and 26 Million euro when simulating the UK statin prescribing pat-
tern (13% decrease in statin costs in 2011). ConClusions: It is crucial to optimize 
prescribing patterns in Portugal, in order to achieve a more rational use of medi-
cines and a sustained control of pharmaceutical expenditure. Besides prescribing 
objeCtives: To review the literature about adherence to warfarin treatment 
in Brazil. Methods: A systematic review of the literature and a wide search 
in LILACS (Literatura Latino Americana e do Caribe em Ciências da Saúde) and 
MEDLINE (Medlars On Line) electronic databases were conducted to identify 
studies with the key words: “warfarin” and “Brazil”. The combination of terms 
was used as reference for the analysis. Search was restricted to randomized con-
trolled trials (RCT), systematic reviews, meta-analysis and prospective clinical 
trials (PCT). Results: A total of 77 studies were identified, from which only 22 
met inclusion criteria: 1 meta-analysis, 5 RCTs, 8 systematic reviews and 8 PCTs. 
Only 1 study described adherence to treatment. From a total of 229 randomized 
patients, 119 received warfarin. Adherence to treatment was observed in 42% 
(p= 0.001) of patients using warfarin considering an average of 57+-18 months 
of follow-up, INR < 2 in 37.54 % and INR > 2 in 11.18 %. Multivariate analysis 
estimated that every 1% of INR < 2, the risk of a thromboembolic event increases 
8.4%. ConClusions: The systematic review of the literature showed lack of 
data regarding Brazilian patients under warfarin treatment. The only available 
study did not define adherence and it did not investigate the underlying causes 
of non-adherence. Thus, it is recommended the conduction of further studies 
in order to provide better understanding of anticoagulant therapies compliance 
in Brazilian patients.
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objeCtives: Potentially avoidable hospitalizations (PAH) are increasing in Spain 
and account for more than 3% of all the discharges. One of the hypothesis to 
explain PAH lies on the suboptimal management of chronic disease at ambulatory 
level of care. In this study we aim at explaining the association between compli-
ance with preventive recommendations in primary care and observed rate of 
PAH. Methods: Compliance with evidence-based preventive recommendations 
regarding diabetes mellitus (DM), chronic heart failure (CHF) and chronic obstruc-
tive pulmonary disease (COPD) was calculated for the 1,350 general practition-
ers of the Basque Health Service and compared with the annual (2011) observed 
rate of PAH between their patients’ panel (mean panel≈1,500 adults; population 
covered= 1,942,873). PAH was defined by a restrictive set of ICD-9 criteria follow-
ing recommendations of the Spanish group of studies on Variability in Medical 
Practice. Multilevel poisson regression was used and age, sex, status socioeco-
nomic (SSE) and hospital of reference were entered as covariates. Results: After 
adjusting by all the covariates, higher compliance of recommendations such as 
periodical spirometry or assessment of the correct use of bronchodilator inhalers 
shows association with lower rates of PAH by COPD (p< 0.05). Periodical foot care, 
oftalmological exam or assessment of the cardiovascular risk is non-significantly 
(0.15≥ p≥ 0.05) but consistently associated to lower rates of PAH by DM. No link was 
observed between compliance or recommendations for CHF and PAH due to this 
cause. The independent effect of the SSE was strong in all the diseases (p< 0.001) 
(higher rates as privation increases). Variations regarding the hospital of refer-
ence were also observed. ConClusions: Adequate compliance of evidence-based 
recommendations limits, modestly but consistently, the incidence of PAH due to 
DM or COPD. The SSE and the hospital of reference explain part of the observed 
variability in hospitalization by chronic disease.
PCV146
Value Chain analysis for CarDiaC DeViCes
Lucas F.1, Tsai P.2
1Pope Woodhead and Associates, St. Ives, UK, 2Cambridge University, Cambridge, UK
objeCtives: We investigated opportunities to cost-effectively improve health out-
comes for patients eligible for ICD, sICD and CRT-D devices. This area was chosen 
because of the high cost of these devices and the significant amount of uncertainty 
on how to use them in a cost effective way. Also, we aimed to explore value-added 
services to patients and physicians, and the area appeared to have potential for 
this. Methods: We conducted a value chain analysis. The first step was to clarify 
the care pathway and identify places where outcome or efficiency were poor; the 
second step was to prioritise the associated problems based on their importance 
(health/cost impact) and the feasibility of addressing the root causes in the short to 
medium term; the third step was to propose ways to address the priority problems 
and add value in the care pathway. To do this, we conducted secondary research, and 
primary research mainly focused on the UK (20 in-depth discussions with cardiolo-
gists, patients and manufacturers). Results: A core issue was the lack of good evi-
dence-based criteria to identify which patients would benefit most from the various 
devices. Referral to device implantation and funding were seen as below the levels 
expected given current clinical and HTA guidelines; the gap might even increase 
given the expectation that future guidelines may call for higher implantation rates. 
The proposed solutions focused on increasing awareness of the guidelines for more 
effective referral to specialist centres, supporting more flexibility in local funding, 
and taking advantage of the rich, continuous data that the devices themselves could 
provide with a view to eventually improve eligibility criteria. ConClusions: It 
is increasingly difficult to achieve health gains through new therapies. Therefore, 
focusing on improving referral and delivery pathways of current therapies may be 
quite effective at increasing health gains and/or efficiency.
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